{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T13:58:57Z","timestamp":1783691937913,"version":"3.55.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.clgc.2022.12.003","type":"journal-article","created":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T22:35:01Z","timestamp":1671748501000},"page":"265-272","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["A Phase 1\/2 Study of Rapamycin and Cisplatin\/Gemcitabine for Treatment of Patients With Muscle-Invasive Bladder Cancer"],"prefix":"10.1016","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3258-2984","authenticated-orcid":false,"given":"Dimitrios","family":"Makrakis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan L.","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine P.","family":"Roudier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Funda","family":"Vakar-Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael P.","family":"Porter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atreya","family":"Dash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9405-3853","authenticated-orcid":false,"given":"George","family":"Schade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Winters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiotun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elahe","family":"Mostaghel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather H.","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Schweizer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6302-5502","authenticated-orcid":false,"given":"Sarah K.","family":"Holt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John L.","family":"Gore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan Y.","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8921-6091","authenticated-orcid":false,"given":"Hung Ming","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4459-0295","authenticated-orcid":false,"given":"Bruce","family":"Montgomery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2022.12.003_bib0001","first-page":"15","article-title":"Epidemiology of bladder cancer","volume":"8","author":"Saginala","year":"2020","journal-title":"Med Sci Basel Switz"},{"key":"10.1016\/j.clgc.2022.12.003_bib0002","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s00345-017-2115-4","article-title":"Patterns and predictors of recurrence after open radical cystectomy for bladder cancer: a comprehensive review of the literature","volume":"36","author":"Mari","year":"2018","journal-title":"World J Urol"},{"key":"10.1016\/j.clgc.2022.12.003_bib0003","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1634\/theoncologist.2015-0440","article-title":"Neoadjuvant chemotherapy for muscle-invasive bladder cancer: a systematic review and two-step meta-analysis","volume":"21","author":"Yin","year":"2016","journal-title":"Oncologist"},{"key":"10.1016\/j.clgc.2022.12.003_bib0004","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.eururo.2005.04.006","article-title":"Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data: advanced bladder cancer (ABC) meta-analysis collaboration","volume":"48","author":"Vale","year":"2005","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2022.12.003_bib0005","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1056\/NEJMoa022148","article-title":"Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer","volume":"349","author":"Grossman","year":"2003","journal-title":"New Engl J Med"},{"key":"10.1016\/j.clgc.2022.12.003_bib0006","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1200\/JCO.2000.18.17.3068","article-title":"Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study","volume":"18","author":"von der Maase","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2022.12.003_bib0007","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1200\/JCO.2010.32.3139","article-title":"International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial","volume":"29","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2022.12.003_bib0008","article-title":"Neoadjuvant chemotherapy for invasive bladder cancer","year":"2005","journal-title":"Cochrane Database System Rev (Online)"},{"key":"10.1016\/j.clgc.2022.12.003_bib0009","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.eururo.2012.05.048","article-title":"A systematic review of neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer","volume":"62","author":"Meeks","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2022.12.003_bib0010","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1007\/s11934-012-0236-2","article-title":"Neoadjuvant chemotherapy for invasive bladder cancer","volume":"13","author":"Sonpavde","year":"2012","journal-title":"Curr Urol Rep"},{"key":"10.1016\/j.clgc.2022.12.003_bib0011","doi-asserted-by":"crossref","first-page":"572.e21","DOI":"10.1016\/j.urolonc.2019.04.027","article-title":"The impact of pathologic response to neoadjuvant chemotherapy on conditional survival among patients with muscle-invasive bladder cancer","volume":"37","author":"Waingankar","year":"2019","journal-title":"Urol Oncol"},{"key":"10.1016\/j.clgc.2022.12.003_bib0012","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/j.eururo.2011.12.010","article-title":"Pathologic downstaging is a surrogate marker for efficacy and increased survival following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive urothelial bladder cancer","volume":"61","author":"Rosenblatt","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2022.12.003_bib0013","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.eururo.2013.06.049","article-title":"Correlation of pathologic complete response with survival after neoadjuvant chemotherapy in bladder cancer treated with cystectomy: a meta-analysis","volume":"65","author":"Petrelli","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2022.12.003_bib0014","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1158\/1541-7786.MCR-16-0387","article-title":"DNA damage induces a secretory program in the quiescent TME that fosters adverse cancer phenotypes","volume":"15","author":"Gomez-Sarosi","year":"2017","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.clgc.2022.12.003_bib0015","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.ccr.2011.03.011","article-title":"Radiation acts on the microenvironment to affect breast carcinogenesis by distinct mechanisms that decrease cancer latency and affect tumor type","volume":"19","author":"Nguyen","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.clgc.2022.12.003_bib0016","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1038\/s41467-018-04010-4","article-title":"The senescence-associated secretory phenotype is potentiated by feedforward regulatory mechanisms involving Zscan4 and TAK1","volume":"9","author":"Zhang","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.clgc.2022.12.003_bib0017","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1038\/ncb3195","article-title":"MTOR regulates the pro-tumorigenic senescence-associated secretory phenotype by promoting IL1A translation","volume":"17","author":"Laberge","year":"2015","journal-title":"Nat Cell Biol"},{"key":"10.1016\/j.clgc.2022.12.003_bib0018","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.4161\/cbt.8.24.9987","article-title":"Inhibition of mammalian target of rapamycin as a therapeutic strategy in the management of bladder cancer","volume":"8","author":"Mansure","year":"2009","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.clgc.2022.12.003_bib0019","doi-asserted-by":"crossref","first-page":"4785","DOI":"10.1158\/1078-0432.CCR-12-0110","article-title":"Phase I studies of sirolimus alone or in combination with pharmacokinetic modulators in advanced cancer patients","volume":"18","author":"Cohen","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clgc.2022.12.003_bib0020","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.urolonc.2018.03.016","article-title":"Mechanistic target of rapamycin (MTOR) protein expression in the tumor and its microenvironment correlates with more aggressive pathology at cystectomy","volume":"36","author":"Winters","year":"2018","journal-title":"Urol Oncol"},{"key":"10.1016\/j.clgc.2022.12.003_bib0021","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1158\/1078-0432.CCR-16-2054","article-title":"Characterization of an abiraterone ultraresponsive phenotype in castration-resistant prostate cancer patient-derived xenografts","volume":"23","author":"Lam","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clgc.2022.12.003_bib0022","doi-asserted-by":"crossref","first-page":"5082","DOI":"10.1158\/1078-0432.CCR-18-1106","article-title":"Divergent biological response to neoadjuvant chemotherapy in muscle-invasive bladder cancer","volume":"25","author":"Seiler","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clgc.2022.12.003_bib0023","doi-asserted-by":"crossref","DOI":"10.1177\/17562872211029779","article-title":"Neoadjuvant immunotherapy for muscle invasive urothelial bladder carcinoma: will it change current standards?","volume":"13","author":"Renner","year":"2021","journal-title":"Ther Adv Urol"},{"key":"10.1016\/j.clgc.2022.12.003_bib0024","doi-asserted-by":"crossref","first-page":"4019","DOI":"10.1158\/1078-0432.CCR-11-0768","article-title":"Molecular pathways: involving microenvironment damage responses in cancer therapy resistance","volume":"18","author":"Sun","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clgc.2022.12.003_bib0025","doi-asserted-by":"crossref","first-page":"12072","DOI":"10.1073\/pnas.211053698","article-title":"Senescent fibroblasts promote epithelial cell growth and tumorigenesis: a link between cancer and aging","volume":"98","author":"Krtolica","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clgc.2022.12.003_bib0026","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1038\/nm.2890","article-title":"Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B","volume":"18","author":"Sun","year":"2012","journal-title":"Nat Med"},{"key":"10.1016\/j.clgc.2022.12.003_bib0027","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1158\/0008-5472.CAN-05-1716","article-title":"The gene expression program of prostate fibroblast senescence modulates neoplastic epithelial cell proliferation through paracrine mechanisms","volume":"66","author":"Bavik","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.clgc.2022.12.003_bib0028","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.cell.2010.09.043","article-title":"DNA damage-mediated induction of a chemoresistant niche","volume":"143","author":"Gilbert","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.clgc.2022.12.003_bib0029","doi-asserted-by":"crossref","first-page":"4321","DOI":"10.1038\/onc.2015.494","article-title":"SFRP2 augments WNT16B signaling to promote therapeutic resistance in the damaged tumor microenvironment","volume":"35","author":"Sun","year":"2016","journal-title":"Oncogene"},{"key":"10.1016\/j.clgc.2022.12.003_bib0030","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1158\/1541-7786.MCR-16-0192","article-title":"Senescent carcinoma-associated fibroblasts upregulate IL8 to enhance prometastatic phenotypes","volume":"15","author":"Wang","year":"2017","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.clgc.2022.12.003_bib0031","doi-asserted-by":"crossref","first-page":"2853","DOI":"10.1371\/journal.pbio.0060301","article-title":"Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor","volume":"6","author":"Copp\u00e9","year":"2008","journal-title":"PLoS Biol"},{"key":"10.1016\/j.clgc.2022.12.003_bib0032","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/ncb3225","article-title":"mTOR regulates MAPKAPK2 translation to control the senescence-associated secretory phenotype","volume":"17","author":"Herranz","year":"2015","journal-title":"Nat Cell Biol"},{"key":"10.1016\/j.clgc.2022.12.003_bib0033","doi-asserted-by":"crossref","first-page":"17414","DOI":"10.1073\/pnas.0809136105","article-title":"Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation","volume":"105","author":"Choo","year":"2008","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.clgc.2022.12.003_bib0034","doi-asserted-by":"crossref","first-page":"3845","DOI":"10.1158\/1078-0432.CCR-20-4548","article-title":"Phase II clinical trial of everolimus in a pan-cancer cohort of patients with mTOR pathway alterations","volume":"27","author":"Adib","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clgc.2022.12.003_bib0035","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.cmet.2014.01.001","article-title":"Rapamycin: one drug, many effects","volume":"19","author":"Li","year":"2014","journal-title":"Cell Metab"},{"key":"10.1016\/j.clgc.2022.12.003_bib0036","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.ajur.2018.06.006","article-title":"Role of gemcitabine and cisplatin as neoadjuvant chemotherapy in muscle invasive bladder cancer: experience over the last decade","volume":"6","author":"Goel","year":"2019","journal-title":"Asian J Urol"},{"key":"10.1016\/j.clgc.2022.12.003_bib0037","first-page":"813","article-title":"Sirolimus and mTOR inhibitors: a review of side effects and specific management in solid organ transplantation","volume":"42","author":"Nguyen","year":"2019","journal-title":"Drug Saf"},{"key":"10.1016\/j.clgc.2022.12.003_bib0038","doi-asserted-by":"crossref","first-page":"3631","DOI":"10.1093\/ndt\/gfm420","article-title":"Pneumonitis associated with sirolimus: clinical characteristics, risk factors and outcome\u2014a single-centre experience and review of the literature","volume":"22","author":"Weiner","year":"2007","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.clgc.2022.12.003_bib0039","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1093\/ndt\/gfh639","article-title":"Nephrotoxicity of rapamycin: an emerging problem in clinical medicine","volume":"20","author":"Marti","year":"2005","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.clgc.2022.12.003_bib0040","doi-asserted-by":"crossref","first-page":"769","DOI":"10.3390\/medicina57080769","article-title":"Neoadjuvant immunotherapy for muscle-invasive bladder cancer","volume":"57","author":"Peyrottes","year":"2021","journal-title":"Medicina (Kaunas)"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767322002610?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767322002610?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:37:07Z","timestamp":1761565027000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767322002610"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["S1558767322002610"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2022.12.003","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Phase 1\/2 Study of Rapamycin and Cisplatin\/Gemcitabine for Treatment of Patients With Muscle-Invasive Bladder Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2022.12.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}